Objectives: Alcohol places a significant burden on the National Health Service (NHS); yet, uptake of cost-effective approaches remains low. Digital interventions may overcome some barriers to delivery. The Drink Less app has evidence of being effective at supporting heavier drinkers to reduce their alcohol intake. In this study, we estimate the longer-term health impacts, cost-effectiveness, and health inequality impact of a large-scale rollout of the Drink Less app.
Methods: We used the Sheffield Alcohol Policy Model to estimate changes in alcohol consumption, hospital admissions, mortality, and NHS costs of 2 rollout scenarios over a 20-year time horizon: (1) a mass media awareness campaign and (2) a targeted drive to embed referral to Drink Less within primary care. We modeled the cost-effectiveness and inequality impact of each approach in a distributional cost-effectiveness analysis.
Results: A mass media campaign is estimated to reduce per capita alcohol consumption by 0.07 units/week and avert 108 556 hospital admissions and 2606 deaths over 20 years, gaining 24 787 quality-adjusted life-years at a net saving to the NHS of £417 million. Embedding in primary care is estimated to reduce consumption by 0.13 units/week, saving 188 452 admissions and 4599 deaths and gaining 38 897 quality-adjusted life-years at a net saving of £590 million. Both scenarios are estimated to reduce health inequalities, with a larger reduction for the primary care approach.
Conclusions: A large-scale rollout of the Drink Less app is estimated to be health improving, cost saving, and reducing health inequalities. Embedding the use of Drink Less within primary care is likely to be the more effective approach.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jval.2024.11.007 | DOI Listing |
JAMA Netw Open
January 2025
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
Importance: During buprenorphine treatment for opioid use disorder (OUD), risk factors for opioid relapse or treatment dropout include comorbid substance use disorder, anxiety, or residual opioid craving. There is a need for a well-powered trial to evaluate virtually delivered groups, including both mindfulness and evidence-based approaches, to address these comorbidities during buprenorphine treatment.
Objective: To compare the effects of the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) vs active control among adults receiving buprenorphine for OUD.
JAMA Netw Open
January 2025
Department of Surgery, University of Washington, Seattle.
Importance: Timely access to care is a key metric for health care systems and is particularly important in conditions that acutely worsen with delays in care, including surgical emergencies. However, the association between travel time to emergency care and risk for complex presentation is poorly understood.
Objective: To evaluate the impact of travel time on disease complexity at presentation among people with emergency general surgery conditions and to evaluate whether travel time was associated with clinical outcomes and measures of increased health resource utilization.
Clin Cancer Res
January 2025
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Purpose: Mesothelin (MSLN) is highly expressed in high grade serous/ endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody drug conjugate directed at MSLN antigen with a tubulin polymerization inhibitor. We assessed safety, activity and pharmacokinetics of the combination AR/bevacizumab (Bev) (ARB) versus weekly paclitaxel (wP)/Bev (PB) in patients with platinum resistant/refractory HGOC (prrHGOC).
View Article and Find Full Text PDFJAMA Pediatr
January 2025
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Importance: Spontaneous reports have indicated that montelukast increases the risk of neuropsychiatric adverse events, and the US Food and Drug Administration added a boxed warning about these risks in 2020. However, the potential mechanism is not well understood, and the observational evidence is scarce, particularly in children.
Objective: To assess the potential association between the use of montelukast and the risk of neuropsychiatric adverse events in children and adolescents.
JAMA Neurol
January 2025
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Importance: Trials have not demonstrated superiority of alteplase or tenecteplase vs standard care in patients with mild stroke and have raised safety concerns. Prourokinase is an alternative fibrinolytic that may have a favorable safety profile, and the benefit-risk profile of prourokinase in mild stroke is unknown.
Objective: To investigate the efficacy and safety of prourokinase in mild ischemic stroke within 4.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!